4 days ago · Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs

It’s a chance at Biocon to work alongside some of the brightest minds in research, healthcare, pharmaceutical, biotechnology & business sector

Biocon is addressing global medical needs through a portfolio of differentiated and high quality, life-saving biotherapeutics. We have used innovative science to bring competition for some of the world’s most expensive medicines through our generics and biosimilars, thus enabling affordable access to advanced therapies for millions of ...

Biocon is an innovation led fully integrated biopharmaceutical company that has developed affordable biosimilars, novel biologics and complex APIs. Leader in fermentation based biopharmaceuticals. Global scale manufacturing set up for biologics, biosimilars.

Report adverse event/ side effects and/or product complaints for Biocon products. Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Biocon is a unique global biopharmaceutical company changing patients’ lives in over 120 countries. From drug discovery to drug delivery, we make life-saving medicines for the most feared diseases, to extend and significantly improve the quality of life.

Our 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely ‘emerging markets’ orientation.

Biocon Biologics has made large investments in India and Malaysia to build global scale capacity to develop world-class human insulin and insulin analogs and has succeeded in expanding access to insulin therapy by pursuing an innovation strategy that is rooted in affordability.

Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other ...

Feb 24, 2025 · Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: “The launch of YESINTEK marks a significant step in our commitment to improving the lives of patients with inflammatory conditions and expanding access to high-quality biosimilars. It also represents our first product launch in the United States since becoming a fully ...